SCHEMBL29447369

SCHEMBL29447369

COc1ccc(CN(c2cscn2)S(=O)(=O)c2ccc(N[C@H]3CCN(C(=O)OC(C)(C)C)C3)c(C)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
STS P08842 1/20 0.41
MMP1 P03956 5/20 0.41
MMP9 P14780 5/20 0.41
MMP3 P08254 4/20 0.41
MMP7 P09237 4/20 0.41
BMP1 P13497 1/20 0.40
PIK3CA P42336 3/20 0.39
PRKDC P78527 2/20 0.39
BRD4 O60885 1/20 0.39
SLC2A1 P11166 1/20 0.39
PIK3CD O00329 1/20 0.39
GPR119 Q8TDV5 2/20 0.38
MMP13 P45452 4/20 0.38
DYRK1A Q13627 1/20 0.38
MTOR P42345 1/20 0.38
MMP8 P22894 3/20 0.37
MMP2 P08253 2/20 0.37
TGFBR1 P36897 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19627723 1.00 ALDH1A1 (0.42) ALDH1A1STSMMP1MMP9MMP3
SCHEMBL28540528 1.00 ALDH1A1 (0.42) ALDH1A1STSMMP1MMP9MMP3
SCHEMBL29447378 0.93 ALDH1A1 (0.41) ALDH1A1STSMMP1MMP9MMP3
SCHEMBL19627721 0.93 ALDH1A1 (0.41) ALDH1A1STSMMP1MMP9MMP3
SCHEMBL28556812 0.92 ALDH1A1 (0.42) ALDH1A1STSMMP1MMP9MMP3
SCHEMBL30845610 0.92 ALDH1A1 (0.42) ALDH1A1STSMMP1MMP9MMP3
SCHEMBL21789465 0.92 ALDH1A1 (0.42) ALDH1A1STSMMP1MMP9MMP3
SCHEMBL19614262 0.91 MMP9 (0.39) MMP1MMP9BMP1MMP13
SCHEMBL19614263 0.91 MMP9 (0.39) MMP1MMP9BMP1MMP13
SCHEMBL19627654 0.90 SCN1A (0.44) ALDH1A1STSMMP1MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B ALDH1A1 2797/4885STS 181/4885MMP1 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.